Vesugen is a synthetic tripeptide (Lys-Glu-Asp, abbreviated “KED,” also called “T-38”) from the Khavinson “bioregulator” family, marketed for vascular and skin/connective-tissue support. Published research on KED is laboratory (cell-culture) and limited animal work, mostly from one Russian research group and close collaborators, with no completed human clinical trial identified. It is sold internationally as an oral capsule or research peptide and is not an approved drug anywhere.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” tripeptide, marketed for vascular and skin/connective-tissue support |
| Primary research interest | Vascular-tissue and skin/connective-tissue support |
| Highest available evidence | Tier 4 — laboratory (cell-culture) and limited animal work, mostly from one Russian research group and close collaborators; no completed human clinical trial identified |
| Human research available | No — no completed human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold as an oral capsule/research peptide |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Vesugen |
| Alternative names | KED (from its Lys-Glu-Asp sequence); also called “T-38” |
| Peptide sequence | Lys-Glu-Asp (“KED”) |
| Amino-acid length | 3 (tripeptide) |
| Molecular formula | Not independently re-verified in this pass |
| Molecular weight | Not independently re-verified in this pass |
| CAS Registry Number | Not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| Peptide class | Khavinson-group “bioregulator” peptide line (Saint Petersburg Institute of Bioregulation and Gerontology) |
| Primary biological target | Not established via receptor-level human data; published laboratory work more often used skin fibroblasts and neuron-like cells than vascular tissue specifically |
| Developer or originator | Saint Petersburg Institute of Bioregulation and Gerontology (Khavinson group) |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Vesugen is one of the short synthetic Khavinson-group peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of a family of organ/tissue-targeted “bioregulator” peptides. The sequence is lysine-glutamate-aspartate (Lys-Glu-Asp, “KED”). It is marketed as a vascular-tissue bioregulator, though the published laboratory work on KED more often used skin fibroblasts and neuron-like cells than vascular endothelial or smooth-muscle cells specifically.
Important sourcing note: some project-facing summaries describe Vesugen using the four-amino-acid sequence “Lys-Glu-Asp-Gly” (KEDG). This conflicts with the tripeptide sequence (Lys-Glu-Asp, KED) that appears consistently across the peer-reviewed literature and Wikipedia’s summary. Separately, some vendor pages apply the KEDG label to a different Khavinson product (“Testagen“). This is a genuine, unresolved naming conflict across sources and should be treated as such rather than silently resolved in either direction.
KED has been examined in human dermal fibroblast aging cultures, bone-marrow mesenchymal stem cell aging models, and (together with EDR and AEDG) in fibroblast-derived induced neurons, generally studied by the same overlapping group of Russian and Italian collaborators. There is no published human trial and no independent Western regulatory review of Vesugen’s claimed mechanisms.
How does it work?
Plain-English explanation
The proposed idea is that this small peptide helps aging skin and connective-tissue cells behave more like younger cells — producing more collagen-supporting proteins, dividing more readily, and showing fewer stress/aging markers. Some of this has been shown in human skin-cell cultures; the vascular-specific claim used in Vesugen’s marketing name has much thinner direct laboratory support.
Technical explanation
In human bone-marrow mesenchymal stem cell aging cultures, KED was reported to increase IGF1 expression, inhibit FOXO1 expression, and affect TNKS2 expression differently depending on the aging model used (Ashapkin et al., 2020, Mol Biol Rep, PMID 32399807, DOI 10.1007/s11033-020-05506-3). In skin fibroblast aging cultures, KED (studied alongside KE, AED, and AEDG) inhibited MMP-9 synthesis and enhanced Ki-67 and CD98hc expression, markers associated respectively with proliferation and reduced cellular aging (Lin’kova et al., 2016, Bull Exp Biol Med, PMID 27259496, DOI 10.1007/s10517-016-3370-x). A 2021 review summarized KED’s reported effects on genes involved in apoptosis, aging, neurogenesis, and Alzheimer’s-disease pathogenesis (p16, p21, NES, GAP43, SUMO, APOE, IGF1), and noted that oral KED had reportedly “improved memory and attention in elderly individuals with functional CNS disorders” in earlier Russian clinical work, though this review did not itself present new trial data and the underlying study was not independently verified in this review (Khavinson et al., 2021, Bull Exp Biol Med, PMID 34173097, DOI 10.1007/s10517-021-05192-6).
Potential benefits and research applications
Skin and connective-tissue cell aging
What is being investigated: whether KED reduces markers of cellular aging in skin fibroblasts and supports extracellular matrix maintenance. How the effect might occur: proposed suppression of matrix-metalloproteinase activity and stimulation of proliferation markers. Evidence: published human cell-culture studies. Strength: preliminary, laboratory tier, from a small, overlapping set of research groups. Limitation: cell-culture findings do not establish a visible or measurable skin benefit in living people.
Neurogenesis and Alzheimer’s-disease-relevant gene expression
What is being investigated: whether KED supports neuronal differentiation markers and modulates genes implicated in Alzheimer’s pathology. How the effect might occur: proposed transcriptional modulation, consistent with other short Khavinson peptides. Evidence: laboratory cell studies and a narrative review referencing an earlier Russian clinical report of oral use in elderly people with cognitive complaints. Strength: preliminary; the cited elderly-cognition finding is referenced only secondhand through a review rather than confirmed against the original clinical report in this entry, so it should be treated cautiously and not as confirmed independent human clinical evidence.
Vascular tissue support (as marketed)
What is being investigated: vendor marketing associates Vesugen with vascular/blood-vessel “regulation.” How the effect might occur: not established for vascular endothelial or smooth-muscle tissue specifically in the literature reviewed. Evidence: none identified specific to vascular cell types. Strength: has not been established; this application appears to follow from the peptide’s organ-bioregulator branding rather than from dedicated vascular research.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
A narrative review references an earlier Russian report of oral KED use improving memory and attention in elderly individuals, but no specific dose, frequency, or duration from that report was independently verified in this review. Not consistently reported.
Amounts studied in animal research
Published work reviewed here is predominantly in vitro (cultured human cells) rather than whole-animal dosing. No verified in vivo animal dose, frequency, or route specific to KED was identified. Not consistently reported.
Practitioner and community-reported protocols
Vendors selling Vesugen as an oral capsule or reconstituted 20 mg vial commonly describe roughly 10-20 mg per day for a 10-20 day course, matching the generic Khavinson-line “bioregulator” template applied across this entire peptide family. This is widely repeated online, but its original source could not be verified as tracing to a specific published clinical protocol for Vesugen.
Explanation of the reported figures
The most frequently repeated figure — roughly 10-20 mg orally per day for 10-20 days — appears essentially identically across vendor pages for many unrelated Khavinson-family peptides, which is strong evidence it is a marketing template rather than a compound-specific finding. The one human-relevant claim in the literature (oral KED improving memory/attention in elderly people) is cited only secondhand in a 2021 review and was not independently traced to and confirmed against its original clinical report in this review; it should not be read as a confirmed, independently verified clinical result. No verified whole-animal dosing data were located. Cell-culture concentrations (nanomolar range) cannot be converted into a human oral dose.
What circulates E5
Vendors and longevity/biohacking communities commonly describe oral Vesugen capsule use at roughly 10-20 mg per day for a 10-20 day course, matching the generic Khavinson-line "bioregulator" course template used across this whole peptide family. This is widely repeated online, but its original source could not be verified, and it does not correspond to any published pharmacokinetic or dedicated clinical dosing study for Vesugen specifically. Treat any specific "X mg/day" figure for Vesugen as community/vendor-tier information only.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No independently verified human trial exists to characterize side effects. As with other unregulated peptide products, purity, accurate labeling, contamination, and correct concentration are not guaranteed for vendor-sold Vesugen. Long-term effects, interactions, and an appropriate human dose have not been established.
Regulatory and developmental status
Vesugen has no drug approval in the United States, European Union, or Russia identified in this review. It is sold as an oral “bioregulator” supplement and research peptide, not as a registered pharmaceutical, and has not entered a recognized clinical trial pipeline. Status verified as of the date below.
Frequently asked questions
What is Vesugen?
A short synthetic tripeptide (Lys-Glu-Asp, “KED”) from the Khavinson bioregulator family, studied mainly in human skin and stem-cell cultures and marketed for vascular support.
Is the Vesugen sequence certain?
The tripeptide KED (Lys-Glu-Asp) is well supported in the peer-reviewed literature, but some sources describe a four-amino-acid “KEDG” sequence for Vesugen, which conflicts with both the science and with other vendors’ use of “KEDG” for a different product (Testagen). This conflict is unresolved.
Has Vesugen been studied in humans?
A narrative review references an earlier Russian human report of cognitive benefit, but this was not independently confirmed in this review; no other completed human clinical trial was identified.
What dosage circulates online?
Vendors commonly describe roughly 10-20 mg oral courses over 10-20 days, but this figure is widely repeated without an identifiable, verifiable original clinical source.
Is Vesugen approved anywhere?
No. It is not an approved medicine in any jurisdiction identified in this review.
What remains unknown?
Whether KED has any effect on vascular tissue specifically, whether the referenced elderly-cognition finding holds up under independent scrutiny, and what oral human dose (if any) is meaningful.
Bottom line
Vesugen (KED) has real, published laboratory evidence in human skin and stem-cell cultures relevant to cellular aging markers, plus a secondhand reference to an earlier human cognitive report that was not independently verified here. It has essentially no direct evidence for its marketed “vascular bioregulator” positioning, and its sequence is inconsistently reported across vendor sources. The oral dosing that circulates commercially is a generic marketing template, not a studied clinical protocol. It remains an unapproved research/supplement peptide.